Printer Friendly Version
Printer Friendly Version
None
In late 2019, a novel coronavirus, now designated SARS-CoV-2, was identified as the cause of an outbreak of acute respiratory illness in Wuhan, China. In February 2020, the World Health Organization (WHO) designated the disease COVID-19 (coronavirus disease 2019). Since the first reports of COVID-19 from China were released, infection has spread worldwide. The WHO declared a public health emergency in late January 2020 as epidemics have grown in many countries all over the world. The greatest risk of contracting the COVID-19 infection is in those individuals with known exposure to a case of confirmed Novel Coronavirus (COVID-19). Healthcare providers should continue to receive guidance on identifying, testing, and treating patients as new information is released from Centers for Disease Control and Prevention (CDC) and local health departments.
Note: The Public Health Emergency (PHE) ended on day 5/11/2023.
This policy describes which codes should and should not be reported for COVID-19 by BCBSMS and AHS State Health Plan Network Providers. Medically necessary criteria to support reporting of COVID-19 testing are defined in the Coronavirus Disease 2019 (COVID-19) Testing Medical Policy which can be found at www.bcbsms.com and/or www.MyAccessBlue.com .
COVID-19 diagnostic testing should not be performed on patients who do not exhibit any symptoms (asymptomatic). When it is determined that a COVID-19 diagnostic test is warranted, the BCBSMS and AHS State Health Plan Network Practitioner/Facility report the applicable procedure(s) and diagnosis code(s) for the COVID-19 laboratory test.
The "DR" (disaster related) condition code should be used when reporting related COVID-19 care for dates of services 1/27/2020 or later service date when submitting facility claims.
Effective February 1, 2021, the following condition codes are submitted on facility claims for patients receiving services for COVID-19 care.
Condition code 90 (Service provided as part of an Expanded Access (EA) approval))
Condition code 91 (Service provided as part of an Emergency Use Authorization (EUA))
Condition code 90 is reported on claims with EA services. The EA program, sometimes referred to as the compassionate use program, allows patients to receive investigational drugs or medical devices outside of an established clinical trial when there are no adequate and available treatment alternatives.
Condition code 91 is reported on claims when patients receive medical services granted a EUA by the United States Food & Drug Administration (FDA). A EUA allows patients to receive treatments that have not yet been granted full FDA approval during a public health emergency when there are no adequate and available treatment alternatives. Several therapies have been granted a EUA for the treatment of COVID-19 including convalescent plasma, remdesivir, and bamlanivimab.
The Centers for Medicare and Medicaid Services (CMS) and American Medical Association (AMA) developed the following new HCPCS codes to identify diagnostic testing for COVID-19.
Effective 2/4/2020
U0001 (CDC 2019 novel coronavirus (2019-NCoV) real-time RT-PCR diagnostic panel)
U0002 (2019-nCoV coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC)
Effective 3/1/2020 through 5/11/2023
G2023 (Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), any specimen source))
G2024 (Specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), from an individual in a skilled nursing facility or by a laboratory on behalf of a home health agency, any specimen source)
Effective 3/1/2020
C9803 (Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])), any specimen source)
Effective 4/14/2020 through 5/11/2023
U0003 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, making use of high throughput technologies as described by CMS-2020-01-R)
U0004 (2019-nCoV Coronavirus, SARS-CoV-2/2019-nCoV (COVID-19), any technique, multiple types or subtypes (includes all targets), non-CDC, making use of high throughput technologies as described by CMS-2020-01-R)
Effective 1/1/2021 through 5/11/2023
+U0005 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), amplified probe technique, CDC or non-CDC, making use of high throughput technologies, completed within two calendar days from date and time of specimen collection. (List separately in addition to either HCPCS code U0003 or U0004)
Effective 3/13/2020
87635 (Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Coronavirus disease [COVID-19], amplified probe technique)
Effective 4/10/2020
86328 Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method (eg, reagent strip); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
86769 Antibody; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
If the testing device (eg, reagent strip) provides an analysis for two antibody classes on a single-step method, 86328 should only be reported once, regardless of the number of antibodies evaluated and reported on the reagent strip. However, if two separate antibodies are tested on two separate single-step assays, 86328 should be reported once for each reagent strip tested. Modifier 59 should be reported for the second reagent strip assay to identify that two distinct analyses were performed.
86769 should be reported only once, if a single immunoglobulin class was tested. However, if multiple assays are performed for antibodies of different immunoglobulin classes, then 86769 should be reported once for each immunoglobulin class. Modifier -59 should be reported for the second assay to identify that two distinct analyses were performed.
Effective 5/20/2020
0202U (Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected)
Effective 6/25/2020
87426 (Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative, multiple-step method; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19])
0223U (Infectious disease (bacterial or viral respiratory tract infection), pathogen-specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected)
0224U (Antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed)
Effective 8/10/2020
86408 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); screen
86409 Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer
0225U Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected
0226U Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma, serum
Effective 9/8/2020
86413 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative
99072 Additional supplies, materials, and clinical staff time over and above those usually included in an office visit or other non-facility service(s), when performed during a Public Health Emergency as defined by law, due to respiratory-transmitted infectious disease
Effective 10/6/2020
0240U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected
0241U Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected
87636 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique
87637 Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique
87811 Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19])
Effective 11/10/2020
87428 Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B
Treatment Codes
Effective 11/10/2020 through 4/16/2021
Q0239 Injection, bamlanivimab-xxxx, 700 mg
M0239 Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring
Effective 11/21/2020 through 1/24/2022
Q0243 Injection, casirivimab and imdevimab, 2400 mg
M0243 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection and post administration monitoring (Description revised 6/3/21)
Effective 2/9/2021 through 1/24/2022
Q0245 Injection, bamlanivimab and etesevimab, 2100 mg
M0245 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring
Effective 5/6/2021 through 1/24/2022
M0244 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
M0246 Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
Effective 5/26/2021 through 4/5/2022
Q0247 Injection, sotrovimab, 500 mg
M0247 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring
M0248 Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency
Effective 6/3/2021 through 1/24/2022
Q0244 Injection, casirivimab and imdevimab, 1200 mg
Effective 6/24/2021
Q0249 Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
M0249 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose
M0250 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with COVID-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose
Effective 7/30/2021 through 1/24/2022
Q0240 Injection, casirivimab and imdevimab, 600 mg
M0240 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring, subsequent repeat doses
M0241 Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence, this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency, subsequent repeat doses
Effective 12/8/2021
Q0220 - (Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg
Q0221 - (Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg
M0220 - (Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring)
M0221 - (Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary’s home that has been made provider-based to the hospital during the COVID-19 public health emergency)
Effective 12/28/2021
C9507 Fresh frozen plasma, high titer COVID-19 convalescent, frozen within 8 hours of collection, each unit
Effective 1/21/2022
J0248 Injection, remdesivir, 1 mg
Effective 2/11/2022
Q0222 Injection, bebtelovimab, 175 mg
M0222 Intravenous injection, bebtelovimab, includes injection and post administration monitoring
M0223 Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID-19 public health emergency
Vaccine Codes
Effective 12/11/2020 (Pfizer-BioNTech COVID-19 Vaccine Ages 12 years and older) through 4/17/2023
91300 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use
Effective 10/29/2021 (Pfizer-BioNTech COVID-19 Vaccine Ages 5 years through 11 years) through 4/17/2023)
91307 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Effective 10/29/2021 (Pfizer-BioNTech COVID-19 Vaccines Ages 12 and older) through 4/17/2023
91305 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Effective 6/17/2022 (Pfizer-BioNTech COVID-19 Vaccines Ages 6 months through 4 years) through 4/17/2023
91308 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Effective 8/31/2022 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 12 years and older)
91312 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use
Effective 10/12/2022 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 5 years through 11 years)
91315 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Effective 12/08/2022 (Pfizer Bivalent COVID-19 Vaccine Ages 6 months through 4 years)
91317 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use
Effective 12/18/2020 (Moderna COVID-19 Vaccine Ages 12 years and older) through 4/17/2023
91301 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use
Effective 10/20/2021 (Moderna COVID-19 Vaccine Booster Ages 18 years and older) through 4/17/2023
91306 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use
Effective 3/29/2022 (Moderna COVID-19 Vaccine Booster Ages 6 years and older) through 4/17/2023
91309 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
Effective 6/17/2022 (Moderna COVID-19 Vaccine Ages 6 months through 5 years) through 4/17/2023
91311 Severe acute respiratory syndrome coronavirus 2 (SARS-Cover-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative-free, 25 mcg/0.25 mL dosage, for intramuscular use
Effective 8/31/2022 (Moderna Bivalent COVID-19 Vaccine Booster (91313) Ages 18 years and older)
Effective 10/12/2022 (Moderna Bivalent COVID-19 Vaccine Booster (91313) Ages 12 years and older)
91313 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use
Effective 10/12/2022 (Moderna Bivalent COVID-19 Vaccine Booster (91314) Ages 6 years through 11 years)
Effective 4/18/2023 (Moderna Bivalent COVID-19 Vaccine (91314) Ages 6 months through 11 years)
91314 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use
Effective 12/08/2022 (Moderna Bivalent COVID-19 Vaccine Booster Ages 6 months through 5 years)
91316 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage, for intramuscular use
Effective 2/27/2021 (Janssen COVID-19 Vaccine Ages 18 years and older)
91303 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, for intramuscular use
Effective 7/13/2022 (Novavax COVID-19 Vaccine Ages 12 years and older)
91304
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage, for intramuscular use
Vaccine Administration Codes
Effective 12/11/2020 (Pfizer-BioNTech COVID-19 Vaccine Ages 12 years and older) through 4/17/2023
0001A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose
0002A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose
0003A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; third dose (Effective 8/12/2021)
0004A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; booster (Effective 9/22/2021)
Effective 10/29/2021 (Pfizer-BioNTech COVID-19 Vaccine Ages 5 years through 11 years) through 4/17/2023
0071A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0072A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
Effective 1/3/2022 (Pfizer-BioNTech COVID-19 Vaccine Ages 5 years through 11 years) through 4/17/2023
0073A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
Effective 5/17/2022 (Pfizer-BioNTech COVID-19 Vaccine Ages 5 years through 11 years) through 4/17/2023
0074A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose
Effective 10/29/2021 (Pfizer-BioNTech COVID-19 Vaccine Ages 12 years and older) through 4/17/2023
0051A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; first dose
0052A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; second dose
0053A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; third dose
0054A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation; booster dose
Effective 6/17/2022 (Pfizer-BioNTech COVID-19 Vaccines Ages 6 months through 4 years) through 4/17/2023
0081A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0082A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
0083A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose
Effective 4/18/2023 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 12 years and older)
0121A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; single dose
Effective 8/31/2022 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 12 years and older)
0124A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation;
additional
dose
(Description revised 4/18/2023)
Effective 4/18/2023 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 5 years through 11 years)
0151A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; single dose
Effective 10/12/2022 (Pfizer-BioNTech Bivalent COVID-19 Vaccine Ages 5 years through 11 years)
0154A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; additional dose (Description revised 4/18/2023)
Effective 4/18/2023 (Pfizer-BioNTech Bivalent COVID-19 Vaccines Ages 6 months through 4 years)
0171A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose
0172A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose
Effective 12/08/2022 (Pfizer Bivalent COVID-19 Vaccine Ages 6 months through 4 years)
0173A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose (Description revised 3/14/2023)
Effective 3/14/2023 (Pfizer Bivalent COVID-19 Vaccine Ages 6 months through 4 years)
0174A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; additional dose (Description revised 4/18/2023)
Effective 12/18/2020 (Moderna COVID-19 Vaccine Ages 12 years and older) through 4/17/2023
0011A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose
0012A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose
0013A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; third dose (Effective 8/12/2021)
Effective 10/20/2021 (Moderna COVID-19 Vaccine Booster Ages 18 years and older) through 4/17/2023
0064A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose
Effective 6/17/2022 (Moderna COVID-19 Vaccine Ages 6 months through 5 years) through 4/17/2023
0111A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; first dose
0112A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose
0113A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus (SARS-Co-V-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose
Effective 6/17/2022 (Moderna COVID-19 Vaccine Booster Ages 6 years through 11 years) through 4/17/2023
0091A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years
0092A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years
0093A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years
Effective 3/29/2022 (Moderna COVID-19 Vaccine Booster Ages 18 years and older) through 4/17/2023
0094A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose, when administered to individuals 18 years and over (Description revised 7/6/22)
Effective 8/31/2022 (Moderna Bivalent COVID-19 Vaccine Booster (0134A) Ages 18 years and older)
Effective 10/12/2022 (Moderna Bivalent COVID-19 Vaccine Booster (0134A) Ages 12 years and older)
0134A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage; additional dose
(Description revised 4/18/2023)
Effective 4/18/2023 (Moderna Bivalent COVID-19 Vaccine Ages 6 months through 11 years)
0141A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; first dose
0142A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; second dose
Effective 10/12/2022 (Moderna Bivalent COVID-19 Vaccine (0144A) Ages 6 years through 11 years)
Effective 4/18/2023 (Moderna Bivalent COVID-19 Vaccine (0144A) Ages 6 years through 11 years)
0144A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRN-LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage; additional dose
(Description revised 4/18/2023)
Effective 12/08/2022 (Moderna Bivalent COVID-19 Vaccine Ages 6 months through 5 years)
0164A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 10 mcg/0.2 mL dosage; additional dose (Description revised 4/18/2023)
Effective 2/27/2021 (Janssen COVID-19 Vaccine Ages 18 years and older)
0031A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x1010 viral particles/0.5mL dosage, single dose
0034A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 10 viral particles/0.5 mL dosage; booster dose (Effective 10/20/2021)
Effective 7/13/2022 (Novavax COVID-19 Vaccine Ages 12 years and older)
0041A Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose
0042A
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose
Effective 10/19/2022 (Novavax COVID-19 Vaccine Booster Ages 18 years and older)
0044A
Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage; booster dose
Effective 6/8/2021 (COVID-19 vaccine home)
M0201 COVID-19 vaccine administration inside a patient's home; reported only once per individual home per date of service when only COVID-19 vaccine administration is performed at the patient's home
For Dates of Service Prior to 4/18/2023
When administering the Pfizer COVID-19 vaccine,the provider should report CPT 91300 for the vaccine product and CPT 0001A for the 1st dose, CPT 0002A for the second dose, CPT 0003A for the third dose for moderately and severely immunocompromised persons, and CPT 0004A for the booster dose. CPT 0004A was authorized for ages 16-17 on 12/9/2021 and for ages 12/15/2021 on 1/5/2022. The second vaccine is administered twenty-one (21) days after the initial vaccine is given. The third vaccine is administered twenty-eight (28) days after the second vaccine is given. The first booster vaccine is administered at least five (5) months after completion of the 2 dose series for healthy individuals or at least three (3) months after the completion of the 3 dose series for immunocompromised individuals. The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product. The second booster must be an mRNA COVID-19 vaccine (Pfizer or Moderna).
When administering the Pfizer ready-to-use vaccine COVID-19 vaccine for ages 12 and older, the provider should report CPT 91305 for the vaccine product and CPT 0051A for the 1st dose, CPT 0052A for the second dose, 0053A for the third dose for moderately and severely immunocompromised persons, and 0054A for the booster. The second vaccine is administered twenty-one (21) days after the initial vaccine is given. The third vaccine is administered twenty-eight (28) days after the second vaccine is given. The first booster vaccine is administered at least five (5) months after completion of the 2 dose series for healthy individuals or at least three (3) months after the completion of the 3 dose series for immunocompromised individuals. The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product. The second booster must be an mRNA COVID-19 vaccine (Pfizer or Moderna).
When administering the Pfizer COVID-19 vaccine for children ages 5-11, the provider should report CPT 91307 for the vaccine product and CPT 0071A for the 1st dose, CPT 0072A for the second dose and CPT 0073A for the third dose for moderately and severely immunocompromised persons. The second vaccine is administered twenty-one (21) days after the initial vaccine is given. The third vaccine is administered twenty-eight (28) days after the second vaccine is given. The first booster vaccine is administered at least five (5) months after completion of the final dose in the primary series for healthy individuals or at least three (3) months after the completion of the 3 dose series for immunocompromised individuals. A second booster dose in this age group has not been authorized by the FDA or recommended by CDC.
When administering the Pfizer COVID-19 vaccine for children ages 6 months through 4 years, the provider should report CPT 91308 for the vaccine product and CPT 0081A for the 1st dose, CPT 0082A for the second dose and CPT 0083A for the third dose for moderately and severely immunocompromised persons. The second dose is administered twenty-one (21) days or more after the initial vaccine is given. The third dose is administered fifty-six (56) days after the second vaccine is given.
When administering the Pfizer-BioNTech Bivalent COVID-19 vaccine booster for ages 12 years and older, the provider should report CPT 91312 for the booster product and CPT 0124A. Individuals are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
When administering the Pfizer-BioNTech Bivalent COVID-19 vaccine booster for ages 5 years through 11 years, the provider should report CPT 91315 for the booster product and CPT 0154A. Individuals are eligible for a single booster dose of the Pfizer-BioNTech COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
When administering the Pfizer Bivalent COVID-19 vaccine for ages 6 months through 4 years, the provider should report CPT 91317 for the vaccine product and CPT 0173A to report administration of the third dose after the administration of the first (0081A) and 2nd (0082A) doses of 91308 product.
When administering the Moderna COVID-19 Vaccine for ages 12 and older, the provider should report CPT 91301 for the vaccine product and CPT 0011A for the 1st dose. CPT 0012A for the second dose and CPT 0013A for the third dose for moderately and severely immunocompromised persons. The second vaccine is administered twenty-eight (28) days after the initial vaccine was given. The third vaccine is administered twenty-eight (28) days after the second vaccine is given. When administering the 50 mcg/0.5mL booster vaccine, the provider should report CPT 91306 for the vaccine product and CPT 0064A for the booster dose. When administering the 50mcg/0.5mL booster vaccine, the provider should report CPT 91309 for the vaccine product and CPT 0094A for the booster dose when administer to individuals 18 years and over. The first booster vaccine is administered at least five (5) months after completion of the 2 dose series for healthy individuals or at least three (3) months after the completion of the 3 doseseries for immunocompromised individuals. The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product. The second booster must be an mRNA COVID-19 vaccine (Pfizer or Moderna).
When administering the Moderna COVID-19 Vaccine for children ages 6 months through 5 years, the provider should report CPT 91311 for the vaccine product and CPT 0111A for the 1st dose. CPT 0112A for the second dose and CPT 0113A for the third dose for moderately and severely immunocompromised persons. The second dose is administered twenty-eight (28) days after the initial vaccine was given. The third dose is administered twenty-eight (28) days after the second vaccine is given.
When administering the Moderna COVID-19 Vaccine for children ages 6-11 years, the provider should report CPT 91309 for the vaccine product and CPT 0091A for the 1st dose. CPT 0092A for the second dose and CPT 0093A for the third dose for moderately and severely immunocompromised persons. The second dose is administered twenty-eight (28) days after the initial vaccine was given. The third dose is administered twenty-eight (28) days after the second vaccine is given.
When administering the Moderna Bivalent COVID-19 vaccine booster for ages 12 years and older, the provider should report CPT 91313 for the booster product and CPT 0134A. Individuals are eligible for a single booster dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
When administering the Moderna Bivalent COVID-19 vaccine booster for ages 6 years through 11 years, the provider should report CPT 91314 for the booster product and CPT 0144A. Individuals are eligible for a single booster dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
When administering the Moderna Bivalent COVID-19 vaccine booster for ages 6 months through 5 years, the provider should report CPT 91316 for the booster product and CPT 0164A. Individuals are eligible for a single booster dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination or have received the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
When administering the Janssen COVID-19 Vaccine, the provider should report CPT 91303 for the vaccine product and CPT 0031A for the single dose and 0034A for the booster dose. The first booster vaccine is administered at least two (2) months after the single dose vaccine. The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product. The second booster must be an mRNA COVID-19 vaccine (Pfizer or Moderna).
When administering the Novavax COVID-19 Vaccine for ages 12 and older, the provider should report CPT 91304 for the vaccine product and CPT 0041A for the single dose and 0042A for the second dose. The second dose is administered at least twenty-one (21) days after the initial vaccine is given.
When administering the Novavax COVID-19 Vaccine booster for ages 18 years and older, the provider should report CPT 91304 for the booster product and CPT 0044A. A first booster dose to the following individuals at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine:
Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate.
Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.
If the sole purpose for the visit is to only administer the COVID-19 vaccine, then only the applicable vaccine and vaccine administration code should be reported. The provider should report ICD-10 diagnosis code, Z23 (Encounter for immunizations) and link it to the vaccine and vaccine administration codes filed on the claim.
For Dates of Service 4/18/2023 and after
When administering the Pfizer-BioNTech Bivalent COVID-19 vaccine for ages 12 years and older, the provider should report CPT 91312 for the vaccine product and CPT 0121A for the 1st dose and CPT 0124A for the additional dose. Individuals are eligible for a single additional dose of the Pfizer-BioNTech COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination.
When administering the Pfizer-BioNTech Bivalent COVID-19 vaccine for ages 5 years through 11 years, the provider should report CPT 91315 for the vaccine product and CPT 0151A for the 1st dose and CPT 0154A for the additional dose. Individuals are eligible for a single additional dose of the Pfizer-BioNTech COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination.
When administering the Pfizer-BioNTech Bivalent COVID-19 vaccine for ages 6 months through 4 years, the provider should report CPT 91317 for the vaccine product and CPT 0171A for the 1st dose, CPT 0172A for the 2nd dose, CPT 0173A for the 3rd dose and CPT 0174A for the additional dose. Three doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent are administered over at least 11 weeks. The first two doses are administered three weeks apart. The third dose is administered at least 8 weeks after the second dose. A fourth dose with Pfizer BioNTech COVID-19 Vaccine, Bivalent may be administered at least 1 month following the most recent dose; additional doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider.
When administering the Moderna Bivalent COVID-19 vaccine for ages 12 years and older, the provider should report CPT 91313 for the vaccine product and CPT 0134A for the additional dose. Individuals are eligible for a single additional dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least two months since they have completed primary vaccination.
When administering the Moderna Bivalent COVID-19 vaccine for ages 6 months through 11 years, the provider should report CPT 91314 for the vaccine product and CPT 0141A for the 1st dose, CPT 0142A for the 2nd dose and CPT 0144A for the additional dose. Individuals are eligible two doses of the Moderna COVID-19 Vaccine Bivalent. The second dose is administered 1 month after the first. Individuals are eligible for a single additional dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least one month since they have completed primary vaccination.
When administering the Moderna Bivalent COVID-19 vaccine for ages 6 months through 5 years, the provider should report CPT 91316 for the vaccine product and CPT 0164A for the additional dose. Individuals are eligible for a single additional dose of the Moderna COVID-19 Vaccine Bivalent if it has been at least one month since they have completed primary vaccination.
When administering the Janssen COVID-19 Vaccine for ages 18 years and older, the provider should report CPT 91303 for the vaccine product and CPT 0031A for the single dose and 0034A for the booster dose. The first booster vaccine is administered at least two (2) months after the single dose vaccine. The recommended interval between the first booster dose and the second booster is at least 4 months, regardless of primary series or first booster dose product. The second booster must be an mRNA COVID-19 vaccine (Pfizer or Moderna).
When administering the Novavax COVID-19 Vaccine for ages 12 years and older, the provider should report CPT 91304 for the vaccine product and CPT 0041A for the 1st dose, 0042A for the 2nd dose. The second dose is administered at least twenty-one (21) days after the initial vaccine is given.
When administering the Novavax COVID-19 Vaccine Booster for ages 18 years and older, the provider should report CPT 91304 for the booster product and CPT 0044A for the booster administration. A first booster dose is given to the following individuals at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine:
Individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate.
Individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.
If the sole purpose for the visit is to only administer the COVID-19 vaccine, then only the applicable vaccine and vaccine administration code should be reported. The provider should report ICD-10 diagnosis code, Z23 (Encounter for immunizations) and link it to the vaccine and vaccine administration codes filed on the claim.
The American Dental Association (ADA) developed the following CDT codes for COVID-19 testing (SARS-CoV-2):
Effective 1/1/2021:
D0604 Antigen testing for a public health-related pathogen, including coronavirus
D0605 Antibody testing for a public health-related pathogen, including coronavirus
Effective 1/1/2022:
D0606 Molecular testing for a public health related pathogen, including coronavirus
The American Dental Association (ADA) developed the following CDT codes for COVID-19 vaccine administration (SARS-CoV-2):
Effective 1/1/2022:
D1701 Pfizer-BioNTech Covid-19 vaccine administration – first dose
D1702 Pfizer-BioNTech Covid-19 vaccine administration – second dose
D1703 Moderna Covid-19 vaccine administration – first dose
D1704 Moderna Covid-19 vaccine administration – second dose
D1705 AstraZeneca Covid-19 vaccine administration – first dose
D1706 AstraZeneca Covid-19 vaccine administration – second dose
D1707 Janssen Covid-19 vaccine administration
BCBSMS and AHS State Health Plan Network Providers (e.g. Practitioners, facilities, laboratories, etc.) should neither perform nor submit claims with one of the following respiratory virus panel tests for testing patients suspected to have COVID-19.
CPT Codes | Description |
86023 | Antibody identification; platelet associated immunoglobulin assay |
87631 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 3-5 targets |
87632 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 6-11 targets |
87633 | Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus (eg, adenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, rhinovirus), includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, multiple types or subtypes, 12-25 targets |
0098U | Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 14 targets (adenovirus, coronavirus, human metapneumovirus, influenza A, influenza A subtype H1, influenza A subtype H3, influenza A subtype H1-2009, influenza B, parainfluenza virus, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumoniae, Mycoplasma pneumoniae) |
0099U | Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 20 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus, coronavirus OC43, human metapneumovirus, influenza A, influenza A subtype, influenza A subtype H3, influenza A subtype H1-2009, influenza, parainfluenza virus, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, human rhinovirus/enterovirus, respiratory syncytial virus, Bordetella pertussis, Chlamydophila pneumonia, Mycoplasma pneumoniae) |
0100U | Respiratory pathogen, multiplex reverse transcription and multiplex amplified probe technique, multiple types or subtypes, 21 targets (adenovirus, coronavirus 229E, coronavirus HKU1, coronavirus NL63, coronavirus OC43, human metapneumovirus, human rhinovirus/enterovirus, influenza A, including subtypes H1, H1-2009, and H3, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, respiratory syncytial virus, Bordetella parapertussis [IS1001], Bordetella pertussis [ptxP], Chlamydia pneumoniae, Mycoplasma pneumoniae) |
BCBSMS and AHS State Health Plan Network Providers should report the appropriate Evaluation and Management (E/M) visit code that represents the service rendered during which the nasopharyngeal and/or oropharyngeal swab specimens were collected for submission to the laboratory for COVID-19 testing. When filing the E/M visit code, the appropriate ICD-10-CM diagnosis code(s) related to COVID-19 must be appended using the Centers for Disease Control and Prevention (CDC) ICD-10-CM Official Coding Guidelines guidance.
For reporting ICD-10 diagnosis codes related to COVID-19, the Centers for Disease Control and Prevention (CDC) provided the following ICD-10-CM Official Coding Guidelines guidance for patients with a confirmed diagnosis of COVID-19, exposure/contact to COVID-19, and signs or symptoms related to COVID-19.
For Services Prior to April 1, 2020
Confirmed Diagnosis of COVID-19 with Respiratory Illnesses
Pneumonia
Report J12.89 (Other Viral pneumonia) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere)
Acute Bronchitis
Report J20.8 (Acute bronchitis due to other specified diagnosis) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere)
Bronchitis Not Otherwise Specified
Report J40 (Bronchitis, not specified as acute or chronic) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere)
Lower Respiratory Infection
Report J22 (Unspecified acute lower respiratory infection) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere)
Respiratory Infection Not Otherwise Specified
Report J98.8 (Other respiratory infection, NOS) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere)
Acute Respiratory Distress Syndrome
Report J80.0 (Acute respiratory distress syndrome) and B97.29 (Other Coronavirus as the cause of diseases classified elsewhere
Contact/Exposure to COVID-19
Exposure to COVID-19 but Ruled Out After Evaluation
Report Z03.818 (Encounter for observation for suspected exposure to other biological agents ruled out)
Exposure to COVID-19 to an Individual with a Confirmed Diagnosis of COVID-19
Report Z20.828 (Contact with and (suspected) exposure to other viral communicable diseases)
Signs and Symptoms without a Definitive Diagnosis of COVID-19
Report R05 (Cough)
Report R06.02 (Shortness of breath)
Report R50.9 (Fever, unspecified
For Services April 1, 2020 through December 31, 2020
ICD-10-CM code U07.1 (COVID-19) should be reported for confirmed cases of COVID-19 beginning April 1, 2020. ICD-10-CM diagnosis code U07.1 is to be reported as the primary diagnosis. To identify pneumonia and all other manifestations, provider should report these conditions as additional ICD-10-CM diagnosis codes.
For COVID-19 infection in pregnancy, childbirth, and the puerperium, diagnosis code O98.5 (Other viral diseases complicating pregnancy, childbirth, and the puerperium) should be reported. The O98.5 is reported as the principal diagnosis followed by U07.1 and any associated manifestation codes.
For unconfirmed cases, interim CDC guidelines of suspected contact/exposure or symptoms should continue to be followed.
Contact/Exposure to COVID-19
Exposure to COVID-19 but Ruled Out After Evaluation
Report Z03.818 (Encounter for observation for suspected exposure to other biological agents ruled out)
Exposure to COVID-19 to an Individual with a Confirmed Diagnosis of COVID-19
Report Z20.828 (Contact with and (suspected) exposure to other viral communicable diseases)
Testing of Asymptomatic Individuals
For asymptomatic individuals who are being screened for COVID-19 and have no known exposure to the virus, and the test results are either unknown or negative
Report Z11.59 (Encounter for screening other viral diseases)
Signs and Symptoms without a Definitive Diagnosis of COVID-19
Report R05 (Cough)
Report R06.02 (Shortness of breath)
Report R50.9 (Fever, unspecified)
For Services January 1, 2021 through September 30, 2021
ICD-10-CM code U07.1 (COVID-19) should be reported for confirmed cases of COVID-19. ICD-10-CM diagnosis code U07.1 is to be reported as the primary diagnosis. To identify multisystem inflammatory syndrome, systemic involvement of connective tissue and all other manifestations, provider should report these conditions as additional ICD-10-CM diagnosis codes.
For COVID-19 infection in pregnancy, childbirth, and the puerperium, diagnosis code O98.5 (Other viral diseases complicating pregnancy, childbirth, and the puerperium) should be reported. The O98.5 is reported as the principal diagnosis followed by U07.1 and any associated manifestation codes.
Pneumonia
Report J12.82 (Pneumonia due to coronavirus disease 2019)
Specified systemic involvement of connective tissue
Report M35.81 (Multisystem inflammatory syndrome)
The following conditions are also reported with this code:
Multisystem inflammatory syndrome in children (MIS-C )
Pediatric inflammatory multisystem syndrome (PIMS)
Report M35.89 (Other specified systemic involvement of connective tissue)
Contact/Exposure to COVID-19
Report Z20.822 (Contact with and (suspected) exposure to COVID-19)
Testing of Asymptomatic Individuals
For asymptomatic individuals who are being screened for COVID-19 and have no known exposure to the virus, and the test results are either unknown or negative
Report Z11.52 (Encounter for screening for COVID-19)
Personal History of COVID-19
Report Z86.16 (Personal history of COVID-19)
Signs and Symptoms without a Definitive Diagnosis of COVID-19
Report R05 (Cough)
Report R06.02 (Shortness of breath)
Report R50.9 (Fever, unspecified)
BCBSMS and AHS State Health Plan Network Providers (e.g. Practitioners, facilities, laboratories) should not submit a claim with ICD-10 diagnosis code B34.2 (Coronavirus infection, unspecified) for COVID-19. The COVID-19 cases have globally been of a respiratory origin; therefore, the site of the infection would not be unspecified. Therefore, it would be inappropriate to report diagnosis code, B34.2.
Any claims submitted related to COVID-19 may be subject to medical records request for coding appropriateness and/or medical necessity review.
For Services October 1, 2021 and After
ICD-10-CM code U07.1 (COVID-19) should be reported for confirmed cases of COVID-19. ICD-10-CM diagnosis code U07.1 is to be reported as the primary diagnosis. To identify multisystem inflammatory syndrome, systemic involvement of connective tissue and all other manifestations, provider should report these conditions as additional ICD-10-CM diagnosis codes.
For COVID-19 infection in pregnancy, childbirth, and the puerperium, diagnosis code O98.5 (Other viral diseases complicating pregnancy, childbirth, and the puerperium) should be reported. The O98.5 is reported as the principal diagnosis followed by U07.1 and any associated manifestation codes.
Pneumonia
Report J12.82 (Pneumonia due to coronavirus disease 2019)
Specified systemic involvement of connective tissue
Report M35.81 (Multisystem inflammatory syndrome)
The following conditions are also reported with this code:
Multisystem inflammatory syndrome in children (MIS-C )
Pediatric inflammatory multisystem syndrome (PIMS)
Report M35.89 (Other specified systemic involvement of connective tissue)
Contact/Exposure to COVID-19
Report Z20.822 (Contact with and (suspected) exposure to COVID-19)
Testing of Asymptomatic Individuals
For asymptomatic individuals who are being screened for COVID-19 and have no known exposure to the virus, and the test results are either unknown or negative
Report Z11.52 (Encounter for screening for COVID-19)
Personal History of COVID-19
Report Z86.16 (Personal history of COVID-19)
Signs and Symptoms without a Definitive Diagnosis of COVID-19
Report R05.1 (Acute cough)
Report R05.8 (Other specified cough)
Report R05.9 (Cough, unspecified)
Report R06.02 (Shortness of breath)
Report R50.9 (Fever, unspecified)
BCBSMS and AHS State Health Plan Network Providers (e.g. Practitioners, facilities, laboratories) should not submit a claim with ICD-10 diagnosis code B34.2 (Coronavirus infection, unspecified) for COVID-19. The COVID-19 cases have globally been of a respiratory origin; therefore, the site of the infection would not be unspecified. Therefore, it would be inappropriate to report diagnosis code, B34.2.
Any claims submitted related to COVID-19 may be subject to medical records request for coding appropriateness and/or medical necessity review.
None
The coding guidelines outline in this Coding Policy should not be used in lieu of the Member’s specific benefits plan language.
3/24/20-Policy drafted
4/21/20-Added codes and guidelines for specimen collection (G2023 and G2024), antibody tests (86328 and 86769), high production tests (U0003 and U0004) and testing of asymptomatic individuals (Z11.59). Removed network laboratories reporting requirements and verbiage.
5/1/20-Added antibody code 86023 and verbiage.
5/20/20- Added panel code 0202U
6/29/20-Added codes 87426, 0223U, and 0224U
8/17/20-Added codes 86408, 86409, 0225U and 0226U and corrected AMA links in the Sources section
9/16/20-Added codes 86413 and 99072.
10/12/20-Added codes 0240U, 0241U, 87636, 87637, and 87811
11/9/20-Added codes Q0239 and M0239
11/19/20-Added code 87428
12/4/20-Added dental codes D0604 and D0605, vaccine and administration codes (91300, 91301, 0001A, 0002A, 0011A, 0012A) and filing instructions, condition codes 90 and 91 and filing instructions, guidelines regarding E/M visits, diagnosis codes J12.82, M35.81, M35.89, Z11.52, Z208.22 and Z86.16
12/7/20-Added HCPCS codes Q0243 and M0243
12/19/20-Added HCPCS add-on code U0005
2/25/21-Added HCPCS codes Q0245 and M0245.
3/01/21-Added Vaccine and administration code 91303 and 0031A.
5/24/21-Revised the effective date for HCPCS codes Q0239 and M0239 from “Effective 11/19/2020” to “Effective 11/19/2020 through 4/16/2021”.
7/30/21- Added HCPCS codes Q0244, Q0247, Q0249, M0247, M0249, and M0250.
8/18/21-Added CPT codes third dose administration codes 0003A and 0013A.
8/25/21-Added HCPCS codes M0201, Q0240, M0240, and M0241.
9/30/21-Added CPT code 0004A.
10/5/21- Added diagnosis codes R05.1, R05.8 and R05.9.
10/29/21-Added CPT Codes 91306, 0034A, and 0064A. Removed verbiage regarding NDCs and added dosage intervals for Moderna and Janssen boosters. Capitalized term “covid-19”.
11/3/21- Added Pfizer vaccine and administration codes for ages 5-11 (91307, 0071A, 0072A) and filing instructions.
12/20/21- Added 1/1/2022 code changes.
1/20/22-Added Pfizer vaccine and administration codes (91305, 0051A, 0052A, 0053A, 0054A and 0073A). Added COVID-19 treatment and administration codes Q0220, M0220 and M0221.
2/11/22 Added J0248. Revised interval of Pfizer and Moderna boosters from 6 months to 5 months. Added and/or clarified requirement for third doses and boosters for Pfizer and Moderna vaccines. Corrected spacing.
3/31/22-Added COVID-19 treatment and administration codes C9057, Q0221, Q0222, M0222, and M0223. Added deletion dates for Q0240, Q0243, Q0244, Q0245, M0240, M0241, M0243, M0244, M0245, and M0246; because the drugs aren’t currently authorized in any U.S region and may not be administered for treatment or post-exposure prevention of COVID-19 under the EUA until further notice by the FDA.
4/8/22-Added deletion date for M0247, M0248, and Q0247; because CDC data estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in al U.S. regions. Due to this data, sotrovimab is not authorized in any U.S. state or territory effective April 5, 2022.
4/21/22-Added Moderna booster and administration codes, 91309 and 0094A. Added recommendations for the second booster for the Pfizer, Moderna, and Janssen vaccines.
6/9/22-Added Pfizer booster administration code, 0074A. Added recommendations for the booster for the Pfizer vaccine for 5-11 year old and added time interval for booster for the immunocompromised for Pfizer and Moderna vaccines.
7/26/22-Added Moderna, Pfizer, and Novavax vaccine and administration codes, 91304, 0041A, 0042A, 91308, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 91311, 0111A, 0112A, 0113A. Revised Moderna code 0094A and
recommendations for
booster administration
for
code 0094A. Added recommendations for the administration for the
Moderna vaccine (6 months-5 years, 6-11 years), Pfizer vaccine
(6 months-4 years)
, Novavax
vaccine (18 years and older
)
and added
time interval for the vaccines.
10/25/22-
Added Moderna B
ivalent
and Pfizer-BioNTech Bivalent vaccine
booster
and administration codes, 91312, 0124A, 91313, and 0134A. Added
Novavax vaccine and administration age range for codes 91304, 0041A and 0042A
. Added recommendations for the administration for the
Moderna B
ivalent
vaccine
booster
(6 years and older) and the Pfizer-
BioNTech Bivalent
vaccine
booster
(5 years and older)
.
10/27/22- Added Novavax vaccine booster administration code 0044A. Added recommendations for the administration Novavax vaccine booster (18 years and older).
12/29/22- Added Moderna Bivalent and Pfizer-BioNTech Bivalent vaccine booster and administration codes 91314, 0144A, 91315, 0154A, 91316, 0164A, 91317 and 0173A. Added recommendations for the administration for the Moderna Bivalentvaccine (6 months - 5 years), Moderna Bivalentvaccinebooster (6 years through 11 years), Pfizer Bivalent Vaccine (6 months - 4 years) and the Pfizer-BioNTech Bivalent vaccine booster(5 years through 11 years).
5/11/23- Added Moderna Bivalent and Pfizer-BioNTech Bivalent new and revised codes. Updated monovalent codes to term use for 4/17/2023. Updated filing instructions for the administration of Moderna Bivalent, Pfizer-BioNTech Bivalent, Janseen and Novavax vaccines for date of service 4/18/2023 and after.
Centers for Disease Control and Prevention (CDC) ICD-10-CM Official Coding Guidelines-Supplement Effective 2/20/2020 https://www.cdc.gov/nchs/data/icd/ICD-10-CM-Official-Coding-Gudance-Interim-Advice-coronavirus-feb-20-2020.pdf .
Centers for Disease Control and Prevention (CDC) ICD-10-CM Official Coding Guidelines-Supplement Effective 3/18/2020 https://www.cdc.gov/nchs/data/icd/Announcement-New-ICD-code-for-coronavirus-3-18-2020.pdf
Centers for Medicare and Medicaid Services (CMS) Press Release CMS Develops Additional Code for Coronavirus Lab Tests https://www.cms.gov/newsroom/press-releases/cms-develops-additional-code-coronavirus-lab-tests
American Medical Association, CPT® releases new coronavirus (COVID-19) code & description for testing https://www.ama-assn.org/practice-management/cpt/cpt-releases-new-coronavirus-covid-19-code-description-testing
April 10, 2020 CPT ® Assistant, https://www.ama-assn.org/system/files/2020-04/cpt-assistant-guide-coronavirus-april-2020.pdf
Centers for Disease Control and Prevention (CDC) ICD-10-CM Official Coding Guidelines for COVID-19 April 1, 2020-September 30, 2020 https://www.cdc.gov/nchs/data/icd/COVID-19-guidelines-final.pdf
Medicare and Medicaid Programs; Policy and Regulatory Revisions in Response to the COVID-19 Public Health Emergency https://www.federalregister.gov/documents/2020/04/06/2020-06990/medicare-and-medicaid-programs-policy-and-regulatory-revisions-in-response-to-the-covid-19-public .
May 20, 2020 CPT ® Assistant, https://www.ama-assn.org/system/files/2020-05/cpt-assistant-guide-coronavirus-may-2020.pdf
June 25, 2020 CPT ® Assistant, https://www.ama-assn.org/system/files/2020-06/cpt-assistant-guide-coronavirus-june-2020.pdf
August 10, 2020 CPT ® Assistant Special Edition: August Update / Volume 30 • 2020, https://www.ama-assn.org/system/files/2020-08/cpt-assistant-guide-coronavirus-august-2020.pdf
September 8, 2020 CPT ® Assistant Special Edition: September Update / Volume 30 • 2020, https://www.ama-assn.org/system/files/2020-09/cpt-assistant-guide-coronavirus-september-2020.pdf
October 6, 2020 CPT ® Assistant Special Edition: October Update / Volume 30 • 2020 https://www.ama-assn.org/system/files/2020-10/cpt-assistant-guide-coronavirus-october-2020.pdf
Medicare Monoclonal Antibody COVID-19 Infusion Program Instruction https://www.cms.gov/files/document/covid-medicare-monoclonal-antibody-infusion-program-instruction.pdf
November 10, 2020 CPT ® Assistant Special Edition: November Update https://www.ama-assn.org/system/files/2020-11/cpt-assistant-guide-coronavirus-november-2020.pdf
April 2020 Special CMC Meeting Summary – Additional Actions for CDT 2021 https://www.ada.org/~/media/ADA/Publications/Files/CMC_Add_CovidPointOfCareTest_ADA_CDBP_2020Apr.pdf?la=en
Special Edition - COVID-19 Antibody Treatment and Enforcement Discretion Reminder https://www.cms.gov/outreach-and-educationoutreachffsprovpartprogprovider-partnership-email-archive/2020-12-03-mlnc-se
CPT ® Assistant Special Edition: Vaccine Coding Development / Volume 30 • 2020 https://www.ama-assn.org/system/files/2020-11/cpt-assistant-guide-covid-vaccine-coding-2020.pdf
CPT ® Assistant Special Edition: December Update / Volume 30 • 2020 https://www.ama-assn.org/system/files/2020-12/cpt-assistant-guide-covid-vaccine-coding-special-edition-2020.pdf
The American Medical Association Appendix Q: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) Vaccines https://www.ama-assn.org/system/files/2020-11/covid-19-immunizations-appendix-q-table.pdf
CPT ® Assistant Special Edition: January Update https://www.ama-assn.org/system/files/2021-01/cpt-assistant-guide-coronavirus-january-2021.pdf
COVID-19 Vaccines and Monoclonal Antibodies https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies
CPT ® Assistant Special Edition: September Update / Volume 31 • 2021 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-september-2021.pdf
American Medical Association’s COVID-19 CPT coding and guidance https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-coding-and-guidance
COVID-19 Vaccines and Monoclonal Antibodies https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies
Centers for Disease Control and Prevention 5 Years of Age and Older Pfizer-BioNTech COVID-19 Vaccine Dosage Chart https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/Pfizer-Dosage-Chart.pdf
Centers for Disease Control and Prevention Moderna COVID-19 Vaccine Preparation and Administration Summary https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/prep-and-admin-summary.pdf
FDA updates Sotrovimab emergency use authorization https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization
CDC Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#recommendations
CPT ® Assistant Special Edition: March Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-march-2022.pdf
CPT ® Assistant Special Edition: April Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-april-2022.pdf
CPT ® Assistant Special Edition: May Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-may-2022.pdf
CPT ® Assistant Special Edition: June Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-june-2022.pdf
CPT ® Assistant Special Edition: July Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-july-2022.pdf
Centers for Disease Control and Prevention https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html
American Medical Association’s COVID-19 CPT vaccine and immunization codes https://www.ama-assn.org/practice-management/cpt/covid-19-cpt-vaccine-and-immunization-codes
Centers for Disease Control and Prevention https://www.cdc.gov/media/releases/2022/s1012-COVID-19-Vaccines.html
FDA COVID-19 Bivalent Boosters https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-bivalent-vaccine-boosters
FDA Novavax COVID-19 Vaccine, Adjuvanted https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/novavax-covid-19-vaccine-adjuvanted
CPT ® Assistant Special Edition: September Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-september-2022.pdf
CPT® Assistant Special Edition: November Update / Volume 32 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-november-2022.pdf
CPT ® Assistant Special Edition December Update / Volume 33 • 2022 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-december-2022.pdf
CPT ® Assistant Special Edition May Update / Volume 33 • 2023 https://www.ama-assn.org/system/files/cpt-assistant-guide-coronavirus-may-2023.pdf
American Medical Association’s COVID-19 CPT vaccine and immunization codes https://www.ama-assn.org/system/files/covid-19-immunizations-appendix-q-table.pdf
FDA Coronavirus Disease 2019 (COVID-19) https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19
2020 ICD-10-CM Complete Code Book by the American Medical Association (AMA)
2020 CPT Professional Edition by the American Medical Association (AMA)
2021 CPT Professional Edition by the American Medical Association (AMA)
2022 CPT Professional Edition by the American Medical Association (AMA)
2023 CPT Professional Edition by the American Medical Association (AMA)